Agilent Technologies (A) has been under a strong bear grip, hence the stock is down -1.42% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.11% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.62% in the last 1 week, and is up 2.89% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.71% and the 50-Day Moving Average is 4.85%.
Agilent Technologies (NYSE:A): The stock opened at $46.96 on Friday but the bulls could not build on the opening and the stock topped out at $46.96 for the day. The stock traded down to $46.55 during the day, due to lack of any buying support eventually closed down at $46.67 with a loss of -0.28% for the day. The stock had closed at $46.80 on the previous day. The total traded volume was 1,202,638 shares.
The company Insiders own 0.32% of Agilent Technologies shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.68% . Institutional Investors own 85.27% of Agilent Technologies shares. During last six month period, the net percent change held by insiders has seen a change of -24.86%. In a related news,The director of Agilent Technologies Inc, Cullen James sold 16,697 shares at $45.78 on May 27, 2016. The Insider selling transaction had a total value worth of $764,389. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business, the diagnostics and genomics business, and the Agilent CrossLab business. The Companys life sciences and applied markets business segment brings together the Companys analytical laboratory instrumentation and informatics. The Companys diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business. The Companys Agilent CrossLab business segment combines its analytical laboratory services and consumables business.